Literature DB >> 28584153

Use of β-Lactam/β-Lactamase Inhibitors for Extended-Spectrum-β-Lactamase Infections: Defining the Right Patient Population.

Pranita D Tamma1, Maria Virginia Villegas2.   

Abstract

In a multicenter, multinational observational study that included neutropenic patients with bloodstream infections by extended-spectrum-β-lactamase-producing species, Gudiol et al. (Antimicrob. Agents Chemother. 61:e00164-17, 2017, https://doi.org/10.1128/AAC.00164-17) demonstrated that β-lactam/β-lactamase inhibitors are effective treatment options. A review of this work, however, reminds us that some lingering questions remain for specific high-risk subgroups.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  ESBL; Gram negative; MDRGN; meropenem; piperacillin-tazobactam

Mesh：

Substances：

Year:  2017        PMID： 28584153      PMCID： PMC5527567          DOI： 10.1128/AAC.01094-17

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  15 in total

1.  Piperacillin-tazobactam as an initial empirical therapy of bacteremia caused by extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae.

Authors:  Cheol-In Kang; So Yeon Park; Doo Ryeon Chung; Kyong Ran Peck; Jae-Hoon Song
Journal:  J Infect       Date:  2012-01-16       Impact factor: 6.072

2.  Inoculum effect on the efficacies of amoxicillin-clavulanate, piperacillin-tazobactam, and imipenem against extended-spectrum β-lactamase (ESBL)-producing and non-ESBL-producing Escherichia coli in an experimental murine sepsis model.

Authors:  F Docobo-Pérez; L López-Cerero; R López-Rojas; P Egea; J Domínguez-Herrera; J Rodríguez-Baño; A Pascual; J Pachón
Journal:  Antimicrob Agents Chemother       Date:  2013-02-25       Impact factor: 5.191

3.  β-Lactam/β-lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli: a post hoc analysis of prospective cohorts.

Authors:  Jesús Rodríguez-Baño; María Dolores Navarro; Pilar Retamar; Encarnación Picón; Álvaro Pascual
Journal:  Clin Infect Dis       Date:  2011-11-04       Impact factor: 9.079

4.  Pharmacokinetics-pharmacodynamics of cefepime and piperacillin-tazobactam against Escherichia coli and Klebsiella pneumoniae strains producing extended-spectrum beta-lactamases: report from the ARREST program.

Authors:  P G Ambrose; S M Bhavnani; R N Jones
Journal:  Antimicrob Agents Chemother       Date:  2003-05       Impact factor: 5.191

5.  Efficacy of β-Lactam/β-Lactamase Inhibitor Combinations for the Treatment of Bloodstream Infection Due to Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae in Hematological Patients with Neutropenia.

Authors:  Carlota Gudiol; Cristina Royo-Cebrecos; Edson Abdala; Murat Akova; Rocío Álvarez; Guillermo Maestro-de la Calle; Angela Cano; Carlos Cervera; Wanessa T Clemente; Pilar Martín-Dávila; Alison Freifeld; Lucía Gómez; Thomas Gottlieb; Mercè Gurguí; Fabián Herrera; Adriana Manzur; Georg Maschmeyer; Yolanda Meije; Miguel Montejo; Maddalena Peghin; Jesús Rodríguez-Baño; Isabel Ruiz-Camps; Teresa C Sukiennik; Cristian Tebe; Jordi Carratalà
Journal:  Antimicrob Agents Chemother       Date:  2017-07-25       Impact factor: 5.191

6.  In vitro and in vivo activities of piperacillin-tazobactam and meropenem at different inoculum sizes of ESBL-producing Klebsiella pneumoniae.

Authors:  Y Harada; Y Morinaga; N Kaku; S Nakamura; N Uno; H Hasegawa; K Izumikawa; S Kohno; K Yanagihara
Journal:  Clin Microbiol Infect       Date:  2014-06-14       Impact factor: 8.067

7.  A Multinational, Preregistered Cohort Study of β-Lactam/β-Lactamase Inhibitor Combinations for Treatment of Bloodstream Infections Due to Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae.

Authors:  Belén Gutiérrez-Gutiérrez; Salvador Pérez-Galera; Elena Salamanca; Marina de Cueto; Esther Calbo; Benito Almirante; Pierluigi Viale; Antonio Oliver; Vicente Pintado; Oriol Gasch; Luis Martínez-Martínez; Johann Pitout; Murat Akova; Carmen Peña; José Molina; Alicia Hernández; Mario Venditti; Nuria Prim; Julia Origüen; German Bou; Evelina Tacconelli; Mario Tumbarello; Axel Hamprecht; Helen Giamarellou; Manel Almela; Federico Pérez; Mitchell J Schwaber; Joaquín Bermejo; Warren Lowman; Po-Ren Hsueh; Marta Mora-Rillo; Clara Natera; Maria Souli; Robert A Bonomo; Yehuda Carmeli; David L Paterson; Alvaro Pascual; Jesús Rodríguez-Baño
Journal:  Antimicrob Agents Chemother       Date:  2016-06-20       Impact factor: 5.191

Review 8.  Determining a clinical framework for use of cefepime and β-lactam/β-lactamase inhibitors in the treatment of infections caused by extended-spectrum-β-lactamase-producing Enterobacteriaceae.

Authors:  Hien M Nguyen; Kileen L Shier; Christopher J Graber
Journal:  J Antimicrob Chemother       Date:  2013-11-20       Impact factor: 5.790

9.  Complete nucleotide sequences of plasmids pEK204, pEK499, and pEK516, encoding CTX-M enzymes in three major Escherichia coli lineages from the United Kingdom, all belonging to the international O25:H4-ST131 clone.

Authors:  Neil Woodford; Alessandra Carattoli; Edi Karisik; Anthony Underwood; Matthew J Ellington; David M Livermore
Journal:  Antimicrob Agents Chemother       Date:  2009-08-17       Impact factor: 5.191

10.  Empiric Piperacillin-Tazobactam versus Carbapenems in the Treatment of Bacteraemia Due to Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae.

Authors:  Tat Ming Ng; Wendy X Khong; Patrick N A Harris; Partha P De; Angela Chow; Paul A Tambyah; David C Lye
Journal:  PLoS One       Date:  2016-04-22       Impact factor: 3.240
View more
  3 in total

1.  The Culture of Carbapenem Overconsumption: Where Does It Begin? Results of a Single-Center Survey.

Authors:  Bryan T Mogle; Robert W Seabury; Zachary Jones; Christopher D Miller; Jeffrey M Steele
Journal:  Hosp Pharm       Date:  2018-05-08

Review 2.  Current trends in the treatment of pneumonia due to multidrug-resistant Gram-negative bacteria.

Authors:  Richard R Watkins; David Van Duin
Journal:  F1000Res       Date:  2019-01-30

Review 3.  Treatment of extended-spectrum β-lactamase-producing Enterobacteriaceae (ESBLs) infections: what have we learned until now?

Authors:  Zoi Dorothea Pana; Theoklis Zaoutis
Journal:  F1000Res       Date:  2018-08-29
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.